Magnus Christensen

Comparisons of CYP1A2 genetic polymorphisms, enzyme activity and the genotype-phenotype relationship in Swedes and Koreans

Roza Ghotbi, Magnus Christensen, Hyung‐Keun Roh et al. · European Journal of Clinical Pharmacology · 2007 · 265 citations

Life Sciences, Genetics, Pharmacology +12

Evaluation of Caffeine as an In Vivo Probe for CYP1A2 Using Measurements in Plasma, Saliva, and Urine

Juan Antonio Carrillo, Magnus Christensen, Sara Ramos et al. · Therapeutic Drug Monitoring · 2000 · 147 citations

Pharmacy, Pharmacokinetics, Pharmacology +13

Low daily 10‐mg and 20‐mg doses of fluvoxamine inhibit the metabolism of both caffeine (cytochrome P4501A2) and omeprazole (cytochrome P4502C19)

Magnus Christensen, Gunnel Tybring, Kazuo Mihara et al. · Clinical Pharmacology & Therapeutics · 2002 · 91 citations

Medicine, Pharmacokinetics, Pharmacology +16

Orally given melatonin may serve as a probe drug for cytochrome P450 1A2 activity in vivo: A pilot study

Sebastian Härtter, Carina Ursing, Sachiyo Morita et al. · Clinical Pharmacology & Therapeutics · 2001 · 56 citations

Medicine, Pharmacokinetics, Pharmacology +17

THE IMPACT OF CYP2C9 GENETICS AND ORAL CONTRACEPTIVES ON CYTOCHROME P450 2C9 PHENOTYPE

Mia Sandberg, Inger Johansson, Magnus Christensen et al. · Drug Metabolism and Disposition · 2004 · 56 citations

Medicine, Genetics, Pharmacology +16